These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

825 related articles for article (PubMed ID: 28143565)

  • 21. Targeting the wee1 kinase for treatment of pediatric Down syndrome acute myeloid leukemia.
    Caldwell JT; Edwards H; Buck SA; Ge Y; Taub JW
    Pediatr Blood Cancer; 2014 Oct; 61(10):1767-73. PubMed ID: 24962331
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Disulfiram/cytarabine eradicates a subset of acute myeloid leukemia stem cells with high aldehyde dehydrogenase expression.
    Yang W; Xie J; Hou R; Chen X; Xu Z; Tan Y; Ren F; Zhang Y; Xu J; Chang J; Wang H
    Leuk Res; 2020 Mar; 92():106351. PubMed ID: 32224355
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Targeting ALDH2 with disulfiram/copper reverses the resistance of cancer cells to microtubule inhibitors.
    Wang NN; Wang LH; Li Y; Fu SY; Xue X; Jia LN; Yuan XZ; Wang YT; Tang X; Yang JY; Wu CF
    Exp Cell Res; 2018 Jan; 362(1):72-82. PubMed ID: 29155365
    [TBL] [Abstract][Full Text] [Related]  

  • 24. RNA expression of genes involved in cytarabine metabolism and transport predicts cytarabine response in acute myeloid leukemia.
    Abraham A; Varatharajan S; Karathedath S; Philip C; Lakshmi KM; Jayavelu AK; Mohanan E; Janet NB; Srivastava VM; Shaji RV; Zhang W; Abraham A; Viswabandya A; George B; Chandy M; Srivastava A; Mathews V; Balasubramanian P
    Pharmacogenomics; 2015 Jul; 16(8):877-90. PubMed ID: 26083014
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Transcriptional regulation of the cystathionine-beta -synthase gene in Down syndrome and non-Down syndrome megakaryocytic leukemia cell lines.
    Ge Y; Jensen TL; Matherly LH; Taub JW
    Blood; 2003 Feb; 101(4):1551-7. PubMed ID: 12393509
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Expression of chromosome 21-localized genes in acute myeloid leukemia: differences between Down syndrome and non-Down syndrome blast cells and relationship to in vitro sensitivity to cytosine arabinoside and daunorubicin.
    Taub JW; Huang X; Matherly LH; Stout ML; Buck SA; Massey GV; Becton DL; Chang MN; Weinstein HJ; Ravindranath Y
    Blood; 1999 Aug; 94(4):1393-400. PubMed ID: 10438727
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A unique role of GATA1s in Down syndrome acute megakaryocytic leukemia biology and therapy.
    Xavier AC; Edwards H; Dombkowski AA; Balci TB; Berman JN; Dellaire G; Xie C; Buck SA; Matherly LH; Ge Y; Taub JW
    PLoS One; 2011; 6(11):e27486. PubMed ID: 22110660
    [TBL] [Abstract][Full Text] [Related]  

  • 28. SAMHD1 is a biomarker for cytarabine response and a therapeutic target in acute myeloid leukemia.
    Schneider C; Oellerich T; Baldauf HM; Schwarz SM; Thomas D; Flick R; Bohnenberger H; Kaderali L; Stegmann L; Cremer A; Martin M; Lohmeyer J; Michaelis M; Hornung V; Schliemann C; Berdel WE; Hartmann W; Wardelmann E; Comoglio F; Hansmann ML; Yakunin AF; Geisslinger G; Ströbel P; Ferreirós N; Serve H; Keppler OT; Cinatl J
    Nat Med; 2017 Feb; 23(2):250-255. PubMed ID: 27991919
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Cytotoxic effect of disulfiram/copper on human glioblastoma cell lines and ALDH-positive cancer-stem-like cells.
    Liu P; Brown S; Goktug T; Channathodiyil P; Kannappan V; Hugnot JP; Guichet PO; Bian X; Armesilla AL; Darling JL; Wang W
    Br J Cancer; 2012 Oct; 107(9):1488-97. PubMed ID: 23033007
    [TBL] [Abstract][Full Text] [Related]  

  • 30. High-dose cytarabine as salvage therapy for relapsed or refractory acute myeloid leukemia--is more better or more of the same?
    Wolach O; Itchaki G; Bar-Natan M; Yeshurun M; Ram R; Herscovici C; Shpilberg O; Douer D; Tallman MS; Raanani P
    Hematol Oncol; 2016 Mar; 34(1):28-35. PubMed ID: 25689584
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Suppressing autophagy enhances disulfiram/copper-induced apoptosis in non-small cell lung cancer.
    Wu X; Xue X; Wang L; Wang W; Han J; Sun X; Zhang H; Liu Y; Che X; Yang J; Wu C
    Eur J Pharmacol; 2018 May; 827():1-12. PubMed ID: 29547841
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Disulfiram modulates stemness and metabolism of brain tumor initiating cells in atypical teratoid/rhabdoid tumors.
    Choi SA; Choi JW; Wang KC; Phi JH; Lee JY; Park KD; Eum D; Park SH; Kim IH; Kim SK
    Neuro Oncol; 2015 Jun; 17(6):810-21. PubMed ID: 25378634
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Novel cell line models to study mechanisms and overcoming strategies of proteasome inhibitor resistance in multiple myeloma.
    Brünnert D; Kraus M; Stühmer T; Kirner S; Heiden R; Goyal P; Driessen C; Bargou RC; Chatterjee M
    Biochim Biophys Acta Mol Basis Dis; 2019 Jun; 1865(6):1666-1676. PubMed ID: 30954557
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The effect of the proteasome inhibitor bortezomib on acute myeloid leukemia cells and drug resistance associated with the CD34+ immature phenotype.
    Colado E; Alvarez-Fernández S; Maiso P; Martín-Sánchez J; Vidriales MB; Garayoa M; Ocio EM; Montero JC; Pandiella A; San Miguel JF
    Haematologica; 2008 Jan; 93(1):57-66. PubMed ID: 18166786
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Effects of PSMB5 on proliferation and bortezomib chemo-resistance in human myeloma cells and its related molecular mechanisms].
    Mo HM; Wu QY; Han DY; Liu R; Ma X; Zhou P; Xu KL
    Zhonghua Xue Ye Xue Za Zhi; 2017 Dec; 38(12):1053-1057. PubMed ID: 29365400
    [No Abstract]   [Full Text] [Related]  

  • 36. Disulfiram when Combined with Copper Enhances the Therapeutic Effects of Temozolomide for the Treatment of Glioblastoma.
    Lun X; Wells JC; Grinshtein N; King JC; Hao X; Dang NH; Wang X; Aman A; Uehling D; Datti A; Wrana JL; Easaw JC; Luchman A; Weiss S; Cairncross JG; Kaplan DR; Robbins SM; Senger DL
    Clin Cancer Res; 2016 Aug; 22(15):3860-75. PubMed ID: 27006494
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Overexpressed mitogen-and stress-activated protein kinase 1 promotes the resistance of cytarabine in acute myeloid leukemia through brahma related gene 1-mediated upregulation of heme oxygenase-1.
    Zhang S; Pan C; Shang Q; Wang W; Hu T; Liu P; Chen S; Wang J; Fang Q
    Eur J Pharmacol; 2022 Feb; 917():174722. PubMed ID: 34953799
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Cytotoxic effect of disulfiram/copper on human cervical cancer cell lines and LGR5-positive cancer stem-like cells.
    Cao HZ; Yang WT; Zheng PS
    BMC Cancer; 2022 May; 22(1):521. PubMed ID: 35534815
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Inactivating PSMB5 mutations and P-glycoprotein (multidrug resistance-associated protein/ATP-binding cassette B1) mediate resistance to proteasome inhibitors: ex vivo efficacy of (immuno)proteasome inhibitors in mononuclear blood cells from patients with rheumatoid arthritis.
    Verbrugge SE; Assaraf YG; Dijkmans BA; Scheffer GL; Al M; den Uyl D; Oerlemans R; Chan ET; Kirk CJ; Peters GJ; van der Heijden JW; de Gruijl TD; Scheper RJ; Jansen G
    J Pharmacol Exp Ther; 2012 Apr; 341(1):174-82. PubMed ID: 22235146
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Inhibition of Mnk enhances apoptotic activity of cytarabine in acute myeloid leukemia cells.
    Li P; Diab S; Yu M; Adams J; Islam S; Basnet SK; Albrecht H; Milne R; Wang S
    Oncotarget; 2016 Aug; 7(35):56811-56825. PubMed ID: 27462781
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 42.